Resverlogix Corp. · TSX:RVX
Resverlogix — Shareholder Meeting (June 2022)
18 slides from Resverlogix's shareholder meeting presentation, Jun 20, 2022
Slide 1: Annual General Meeting June 2022
Annual General Meeting June 2022
Slide 2: Forward Looking Statement
2 Forward Looking Statement This presentation may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends"
Slide 3: Key Highlights
3 Key Highlights Apabetalone is a first-in-class Phase 3 asset with a demonstrated cardio-protective benefit in high-risk cardiovascular, diabetic, and chronic kidney disease patients – utilizing advanced epigenetics to regulate expression of multiple disease-causing genes FDA Breakthrough Therapy D
Slide 4: Key Milestones
4 Resverlogix: Key Milestones May FDA Type C Meeting November announced for The Kingdom of Morocco’s April Phase 3 COVID trial Ministry of Health support EVERSANA™ (CORAL). Phase 2 no September COVID-19 trial extends the scope longer required PAH trial successfully February of their work to June com
Slide 5: Recent Advancements
5 Clinical Programs: Recent Advancements We are a global leader in the development of epigenetic therapies for the treatment of chronic disease
Slide 6: Therapeutic Product Development
6 Four Pillars: Therapeutic Product Development 1 2 3 Intellectual Property Regulatory Approval Commercialization & Academic Support Pathway Strategy & Capacity Financing • Multiple patents • Breakthrough Therapy • Expanded partnership • Industry-wide • Coverage to 2040 Designation with EVERSANA™ do
Slide 7: Severe Industry-wide Downturn
7 Biotechnology Market: Severe Industry-wide Downturn Biotech Performance by Market Cap since XBI High (Feb 2021) $50-200M $200-500M $500M-1B $1-5B $5-10B $10+B XBI 0% -10% -10% -13% -20% -30% -40% -50% -52% -60% -62% -60% -70% -64% -64% -67% -67% Average Median -80% -78% -77% -75% -76% Source: Rapp
Slide 8: BETonMACE2 Clinical Trial Timelines
8 Clinical Trial Timelines: Accelerated Development with Interim Analyses 2022 2023 2024 H2 H1 H2 H1 H2 Planning Planning & Documents Finalization Start-up Start-up BETonMACE2 Recruitment First Patient In Screening & Recruitment Last Patient In Treatment & Study Follow-up Analysis Interim Analysis (
Slide 9: Registration Enabling Design
9 BETonMACE2: Registration Enabling Design BETonMACE2 will be larger and have a greater concentration of patients in the subgroups where apabetalone has the most benefit BETonMACE BETonMACE2 Sample Size 2418 3600 Low eGFR 12% 25% SGLT2i or DPP4i 22% 100% Approximate Cost $80MM Resverlogix Cost $40MM
Slide 10: Treating Patients Who Stand to Benefit the Most
10 BETonMACE2: Treating Patients Who Stand to Benefit the Most BETonMACE Study population p = 0.03 eGFR < 60 mL/min/1.73m2 p = 0.01 SGLT2i or DPP4i Co-administration p = 0.0002 0.0 0.5 1.0 1.5 MACE Hazard Ratio (95% Confidence Interval) Composite endpoint of myocardial infarction, stroke, cardiovasc
Slide 11: COVID-19 Program Update and Progress
11 COVID-19 Program Update and Progress
Slide 12: The Pandemic Continues to Unfold
12 The Pandemic Continues to Unfold 2020 2021 2022 Apabetalone can play an important role in preventing negative outcomes in COVID-19 Source: WHO, COVID-19 case counts by region (June 2022)
Slide 13: Scientific Advisory Board
13 COVID-19 Program: Scientific Advisory Board • A team of highly engaged, experienced, and respected COVID-19 clinical trial investigators • Infectious Disease, Critical and Emergency Care Specialists
Slide 14: A Unique Dual-mechanism
14 Apabetalone in COVID-19: A Unique Dual-mechanism 1 Anti-viral 2 Anti-inflammatory Apabetalone blocks cellular entry of SARS-CoV-2 Apabetalone prevents runaway inflammatory by reducing expression of the key receptor ACE2 responses to the virus, which drive severe outcomes
Slide 15: Apabetalone and Disease Progression
15 COVID-19: Apabetalone and Disease Progression Hyper-inflammatory Early Infection Pulmonary Phase Chronic COVID-19 Phase Asymptomatic Mild to Moderate Symptoms Severe to Critical Symptoms Ongoing Symptoms (~35%) (~45%) (~20%) (~10%) Viral Growth and Activity Host Inflammatory Response Point of Inf
Slide 16: We Thrive on Solid Partnership
16 We Thrive on Solid Partnership 100% of the Top 25 Bio-pharma Companies 570 500 MDs, RNs, Life Science PharmDs Clients 5,000 80 100 Countries Employees Therapeutic Served Areas 25 25 Patient Locations Service Programs 150 Brands We partnered with EVERSANA™ to support the development of apabetalone
Slide 17: EVERSANA's Dedicated Commercialization Team
17 Aligned Objectives: EVERSANA™’s Dedicated Commercialization Team DEDICATED LEADERSHIP TEAM CHIEF COMMERCIAL OFFICER/COMMERCIAL LEADER PATIENT PROJECT LAUNCH MARKETING PAYER SALES CHANNEL SERVICES MANAGEMENT LAUNCH HUB 3PL HCP, GROSS FIELD MARKET FIELD COMPLIANCE GLOBAL DATA & PLAYBOOK/ SERVICES &
Slide 18: Contact
18 Contact: Donald McCaffrey, President & CEO Email: don@resverlogix.com Phone: 587-390-8887 Website: www.resverlogix.com